Spartan's test is for the rapid, near-patient determination of a cardiac patient's genotype for aid in determining appropriate antiplatelet treatment.
Enzyre said its platform technology, which requires a small volume of blood, is able to measure up to 12 reactions simultaneously with high sensitivity and specificity.
The companies will develop an integrated clinical pathology solution with plans to submit a 510(k) application to the US Food and Drug Administration.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
HalioDx will perform immune biomarker exploratory work for the collaboration, which will focus on defining the profile of responder patients to Tedopi.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.
Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease and breast cancer.
The collaboration will align diagnostic placement with treatment capacity for tuberculosis and HIV, among other diseases.
The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.